Published in Cancer Weekly, May 28th, 2002
"These presentations provide further evidence of the novel mechanism of action of Xcytrin to enhance the effects of radiation and chemotherapy for the potential treatment of cancer and other diseases, which is currently being tested in clinical trials," said Richard A. Miller, MD, Pharmacyclics' president and chief executive officer. "Xcytrin is the first of an entirely...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.